GlaxoSmithKline faces fresh drug bribery claims in Syria

GSK – one of the few big firms still supplying drugs in Syria – said on Monday it would investigate the new claims involving its own staff and local distributors.
The company added it had suspended relations with its Syrian distributors pending results of the probe.
The attack on the drugmaker’s ethical standards follows a series of similar bribery claims against the company in China, Iraq, Jordan, Lebanon and Poland. Continue Reading